|
FY2021
12 months to Nov 30, 2021
|
|
|---|---|
| Revenue | |
| Excise taxes | |
| Net revenue | |
| Canada | |
| United States and International | |
| Domestic | |
| Foreign | |
| Total net revenue | |
| Cost of sales | |
| Inventory valuation allowance | |
| Gross profit, excluding fair value items | |
| Fair value changes on growth of biological assets | |
| Realized fair value changes on inventory sold or impaired | |
| Gross profit | |
| Canada | |
| United States and International | |
| Total gross profit | |
| Operating expenses | |
| General and administrative | |
| Selling and marketing | |
| Depreciation and amortization | |
| Share-based payments | |
| Impairment loss | |
| Restructuring charges | |
| Canada | |
| United States and International | |
| Total operating expenses | |
| Loss from operations | |
| Canada | |
| United States and International | |
| Total loss from operations | |
| Other income (expense) | |
| Financing costs, net | |
| Remeasurement of contingent consideration | |
| Foreign exchange gain (loss) | |
| Gain (loss) on disposal of capital assets | |
| Gain on marketable securities and derivatives | |
| Other income | |
| Other income (expense) | |
| Loss before income taxes | |
| Provision for (recovery of) income taxes | |
| Current | |
| Deferred | |
| Income taxes | |
| Loss for the year | |
| Canada | |
| United States and International | |
| Total loss for the year | |
| Basic loss per common share | |
| Diluted loss per common share | |
| Other comprehensive income | |
| Foreign currency translation income, net of tax | |
| Comprehensive loss for the year | |
| Weighted average number of common shares outstanding | |
| Basic | |
| Diluted |
Loading...
